Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stuart Ditchek

General Practice Brooklyn, NY Medical Doctor

NPI 1528068103 CMS profile 1382521

1762 E 23Rd St, Brooklyn, NY 11229

Open in the dashboard

General payments

$170,990

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stuart Ditchek of Brooklyn, NY is reported in the CMS Open Payments database as having received $170,990 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51,772 45
2024 General $64,986 50
2023 General $28,975 42
2022 General $18,295 20
2021 General $1,975 6
2020 General $2,241 9
2019 General $2,746 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stuart Ditchek
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Stuart Ditchek were reported at $51,772. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Stuart Ditchek General Practice median Middle half National median
2019 $2,746 $107 $37–$285 $163
2020 $2,241 $75 $25–$213 $114
2021 $1,975 $93 $30–$272 $132
2022 $18,295 $103 $36–$279 $149
2023 $28,975 $106 $34–$276 $160
2024 $64,986 $114 $39–$290 $164
2025 $51,772 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $170,666 162 payments
  2. GlaxoSmithKline, LLC. $210 12 payments
  3. Sanofi Pasteur Inc. $75 4 payments
  4. Pfizer Inc. $22 1 payment
  5. ALK-Abello, Inc $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $137,257 56 payments
  2. Travel and Lodging $29,767 69 payments
  3. Food and Beverage $3,965 55 payments
Products named General payments · program years 2019–2025
  1. CEREZYME Genetic Disease $128,241 119 payments
  2. CERDELGA Genetic Disease $114,504 102 payments
  3. CEREZYME Rare Disease Genetics $2,686 4 payments
  4. CERDELGA Rare Disease Genetics $2,686 4 payments
  5. BEXSERO $210 12 payments
  6. VAXELIS $61 3 payments
  7. BEYFORTUS $40 2 payments
  8. MENQUADFI $40 2 payments
  9. FLUZONE QUADRIVALENT NORTHERN HEMISPHERE $40 2 payments
  10. PREVNAR 13 $22 1 payment
  11. Other $118 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record